David Cullinane (Waterford, Sinn Fein) | Oireachtas source

This is the concern that is being shared by the industry. It states the US will be watching this with regard to anything that makes it more difficult for a company to protect its intellectual property, particularly when there is large investment in high-tech drugs, and we all know how important that is for patients and the industry. I get that there is a balance to be struck. I get all of these points. I fully understand the issues relating to affordability and access. There is a balance to be struck and this will play out. What is Mr. O'Connor's understanding of the process? We are being told by industry that this will end up on the floor of the European Parliament.